{"id":"NCT00314249","sponsor":"Forest Laboratories","briefTitle":"Study of Milnacipran for the Treatment of Fibromyalgia","officialTitle":"A Phase III Pivotal, Multicenter, Double-blind, Randomized, Placebo-Controlled Monotherapy Study of Milnacipran for the Treatment of Fibromyalgia.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-04","primaryCompletion":"2008-06","completion":null,"firstPosted":"2006-04-13","resultsPosted":"2009-11-02","lastUpdate":"2010-01-20"},"enrollment":1025,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Fibromyalgia"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Milnacipran 100mg","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Milnacipran","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to demonstrate the efficacy and safety of milnacipran at a dosage of 100 mg/day in the treatment of the fibromyalgia syndrome or the pain associate with fibromyalgia.","primaryOutcome":{"measure":"Composite Syndrome Responder Status","timeFrame":"At the end of the three-month stable dose treatment phase","effectByArm":[{"arm":"Placebo","deltaMin":56,"sd":null},{"arm":"Milnacipran","deltaMin":103,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":11},"locations":{"siteCount":24,"countries":["United States"]},"refs":{"pmids":["22429066","20496365"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":509},"commonTop":["Nausea","Headache","Constipation","Insomnia","Dizziness"]}}